We first show here that there are no significant differences in CD47 levels between samples at different cancer stages, although patients with the lowest expression of CD47 show significant better progression-free survival, after correcting for the presence of BAP1, GNAQ, and GNA11 mutations. Here, GNAQ is linked to cancer.